Humanized mice – immunodeficient mice engrafted with functional human cells – have become increasingly important for the study of human diseases (Walsh et al, 2017).
Although “classical” mouse studies are extremely important to understand basic biological processes, there are limitations to mouse studies when investigating human biology (Mestas et al., 2004). Especially cancer and cancer immunotherapy research lead to a growing need for faithful mouse models that recapitulate the complexity of human malignancy and immune contexture within the tumor microenvironment (Olson et al., 2018). Human xenograft models, using human cell lines injected into immunodeficient mice, are common models to evaluate cytotoxic therapies in cancer, but do not reflect intra-tumor heterogeneity and should preferably be used in relatively early stages of drug development (Murayama, 2019). PDX models, in which tumor samples obtained from patients are transplanted into immunodeficient mice, resemble better the original tumors in patients and have therefore higher predictive value in drug development studies (Murayama, 2019). Next generation PDX models are additionally engrafted with human immune cells and are valuable models for immune-based therapies (Murayama, 2019).
Histological analysis of humanized mouse models is impeded, as widely used antibodies have often been developed to function in many species and thus do not discriminate between human and mouse components in humanized mouse models.
HistoSure Xenograft Pathology antibodies are specially designed and developed to fill this antibody gap.